3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
Myeloid
1
Conditions
Mucositis
4
Hematologic Neoplasms
3
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Graft vs Host Disease
1
Interventions
Cyclophosphamide
131
fludarabine phosphate
108
Mycophenolic Acid
92
Peripheral Blood Stem Cell Transplantation
91
Whole-Body Irradiation
80
Tacrolimus
78
Busulfan
64
Cyclosporine
60
fludarabine
55
Melphalan
55
Filgrastim
54
Antilymphocyte Serum
48
Methotrexate
41
Radiotherapy
39
Etoposide
35
Rituximab
33
Granulocyte Colony-Stimulating Factor
27
Sirolimus
25
Cytarabine
23
Stem Cell Transplantation
21
Cord Blood Stem Cell Transplantation
21
thymoglobulin
20
Thiotepa
19
Methylprednisolone
18
sargramostim
17
Cyclosporins
16
Carmustine
16
Alemtuzumab
16
Therapeutics
13
Psychiatric Rehabilitation
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
angiotensin I (1-7)
×
Other hematologic neoplasm
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled